From: Cellular immunotherapy for refractory hematological malignancies
Recipient eligibility criteria | |
---|---|
Inclusion Criteria | Age ≥ 18 |
Histologic confirmation of the following leukemias/lymphomas: | |
• Mantle cell lymphoma with Ki-67>30% | |
• Diffuse Large Cell Lymphoma | |
• Burkitts Lymphoma | |
• Systemic T Cell Lymphomas | |
• Acute Myeloid Leukemia | |
• Acute Lymphoblastic Leukemia | |
Recurrence or progression of disease after at least 1 prior standard treatment | |
Progression of disease within 6 months of last treatment | |
No available curative treatment option | |
≥ 4-weeks since prior chemotherapy or radiation (Exception: Hydroxyurea may be utilized up to 48 hours prior to treatment) | |
Life expectancy of 2 months at treatment initiation | |
≥ 6 months post autologous stem cell transplant | |
DLCO ≥ 40% with no symptomatic pulmonary disease. | |
LVEF ≥ 40% by MUGA or echocardiogram. | |
Creatinine ≤ 2.0 mg/dl, Total bilirubin <1.5x the upper limit of normal (ULN), AST < 3x ULN | |
Non-pregnant and willing to use appropriate birth control during study period | |
Exclusion criteria | Previous allogeneic stem cell transplant |
Previous purine analog (fludarabine, pentostatin, 2-CDA) or alemtuzumab within 1 year of entering the study | |
CML, CLL, multiple myeloma, and indolent lymphoma (follicular lymphoma, marginal zone lymphoma) | |
HLA antibodies to donor HLA type | |
HIV-1 or 2 positive | |
Oxygen dependant COPD | |
Failure to demonstrate adequate compliance with medical therapy and follow-up | |
Significant medical or psychiatric illness that would impair the ability to participate in protocol therapy | |
Active systemic infection |